EA200970535A1 - Антибактериальные производные хинолина - Google Patents

Антибактериальные производные хинолина

Info

Publication number
EA200970535A1
EA200970535A1 EA200970535A EA200970535A EA200970535A1 EA 200970535 A1 EA200970535 A1 EA 200970535A1 EA 200970535 A EA200970535 A EA 200970535A EA 200970535 A EA200970535 A EA 200970535A EA 200970535 A1 EA200970535 A1 EA 200970535A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
pharmaceutically acceptable
quinoline
bacterial infection
formula
Prior art date
Application number
EA200970535A
Other languages
English (en)
Other versions
EA016733B1 (ru
Inventor
Жером Эмиль Жорж Гийемон
Давид Франсис Ален Лансуа
Исмет Доранж
Кунрад Йозеф Лодевейк Марсель Андрис
Анил Коул
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970535(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200970535A1 publication Critical patent/EA200970535A1/ru
Publication of EA016733B1 publication Critical patent/EA016733B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Настоящее изобретение относится к новым замещенным производным хинолина согласно общей формуле (Ia) или формуле (Ib), включая их любую стереохимически изомерную форму, их N-оксид, их фармацевтически приемлемую соль или их сольват. Заявленные соединения применимы для лечения бактериальной инфекции. Также заявлены композиция, включающая в себя фармацевтически приемлемый носитель и в качестве активного ингредиента терапевтически эффективное количество заявленного соединения, применение заявленных соединений или композиций для производства лекарственного средства для лечения бактериальной инфекции и способ получения заявленных соединений.
EA200970535A 2006-12-06 2007-12-04 Антибактериальные производные хинолина EA016733B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06
PCT/EP2007/063313 WO2008068267A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (2)

Publication Number Publication Date
EA200970535A1 true EA200970535A1 (ru) 2009-10-30
EA016733B1 EA016733B1 (ru) 2012-07-30

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970535A EA016733B1 (ru) 2006-12-06 2007-12-04 Антибактериальные производные хинолина

Country Status (33)

Country Link
US (1) US8415475B2 (ru)
EP (1) EP2099758B1 (ru)
JP (1) JP5466011B2 (ru)
KR (1) KR101490222B1 (ru)
CN (2) CN101553470A (ru)
AP (1) AP2479A (ru)
AR (1) AR064151A1 (ru)
AU (1) AU2007328887B2 (ru)
BR (1) BRPI0720220B8 (ru)
CA (1) CA2669819C (ru)
CL (1) CL2007003514A1 (ru)
CY (1) CY1117766T1 (ru)
DK (1) DK2099758T3 (ru)
EA (1) EA016733B1 (ru)
ES (1) ES2573689T3 (ru)
HK (1) HK1208437A1 (ru)
HR (1) HRP20160585T1 (ru)
HU (1) HUE028769T2 (ru)
IL (1) IL199083A (ru)
JO (1) JO3271B1 (ru)
ME (1) ME02498B (ru)
MX (1) MX2009005978A (ru)
MY (1) MY181645A (ru)
NO (1) NO341983B1 (ru)
NZ (1) NZ576823A (ru)
PL (1) PL2099758T3 (ru)
PT (1) PT2099758E (ru)
RS (1) RS54794B1 (ru)
SI (1) SI2099758T1 (ru)
TW (1) TWI406659B (ru)
UA (1) UA100972C2 (ru)
WO (1) WO2008068267A1 (ru)
ZA (1) ZA200903950B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
CN104254528B (zh) 2012-04-27 2017-06-06 詹森药业有限公司 抗菌的喹啉衍生物
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
SI2909192T1 (sl) 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Metilensko vezani kinolinilni modulatorji za ROR-gama-t
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
AU2014334616A1 (en) 2013-10-15 2016-04-28 Janssen Pharmaceutica Nv Quinolinyl modulators of RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CA2954872C (en) 2014-07-14 2019-08-13 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
IL310920A (en) * 2015-01-27 2024-04-01 Janssen Pharmaceutica Nv dispersible preparations
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
AU2017229128B2 (en) * 2016-03-07 2022-04-07 Janssen Pharmaceutica Nv Antibacterial compounds and uses thereof
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
EP3746438A1 (en) * 2018-01-29 2020-12-09 Cadila Healthcare Limited Heterocyclic compounds useful as antibacterial agents
IL302095A (en) * 2020-10-22 2023-06-01 Lunella Biotech Inc Mitochondrial ATP inhibitors targeting the gamma subunit prevent metastasis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270123A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
BRPI0312927B8 (pt) 2002-07-25 2021-05-25 Janssen Pharmaceutica Nv "compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados".
ES2306082T3 (es) 2004-01-23 2008-11-01 Janssen Pharmaceutica Nv Quinolinas sustituidas y su utilizacion como inhibidores micobacterianos.
SG166019A1 (en) 2004-01-23 2010-11-29 Janssen Pharmaceutica Nv Quinoline derivatives and use thereof as mycobacterial inhibitors
CN1910154B (zh) 2004-01-29 2011-08-17 詹森药业有限公司 用作分枝杆菌抑制剂的喹啉衍生物
ES2306146T3 (es) 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
JP2008515395A (ja) 2004-09-28 2008-05-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 細菌のａｔｐ合成酵素の結合ドメイン
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
TWI406659B (zh) 2013-09-01
AU2007328887B2 (en) 2013-01-17
IL199083A (en) 2014-08-31
KR101490222B1 (ko) 2015-02-05
AU2007328887A1 (en) 2008-06-12
BRPI0720220B1 (pt) 2020-06-09
JP2010511668A (ja) 2010-04-15
AP2009004874A0 (en) 2009-06-30
KR20090086604A (ko) 2009-08-13
MY181645A (en) 2020-12-30
HRP20160585T1 (hr) 2016-06-17
NO341983B1 (no) 2018-03-05
CN101553470A (zh) 2009-10-07
JO3271B1 (ar) 2018-09-16
MX2009005978A (es) 2009-06-16
HK1208437A1 (en) 2016-03-04
AP2479A (en) 2012-09-27
ES2573689T3 (es) 2016-06-09
EP2099758A1 (en) 2009-09-16
HUE028769T2 (en) 2017-01-30
CN104744361A (zh) 2015-07-01
US8415475B2 (en) 2013-04-09
AR064151A1 (es) 2009-03-18
CN104744361B (zh) 2021-06-08
JP5466011B2 (ja) 2014-04-09
RS54794B1 (sr) 2016-10-31
CY1117766T1 (el) 2017-05-17
DK2099758T3 (en) 2016-06-13
US20100048566A1 (en) 2010-02-25
PL2099758T3 (pl) 2016-08-31
CL2007003514A1 (es) 2008-07-11
UA100972C2 (ru) 2013-02-25
BRPI0720220A2 (pt) 2013-12-24
BRPI0720220B8 (pt) 2021-05-25
ME02498B (me) 2017-02-20
TW200838528A (en) 2008-10-01
EA016733B1 (ru) 2012-07-30
NO20092542L (no) 2009-08-25
EP2099758B1 (en) 2016-03-09
ZA200903950B (en) 2010-08-25
WO2008068267A1 (en) 2008-06-12
CA2669819A1 (en) 2008-06-12
SI2099758T1 (sl) 2016-07-29
NZ576823A (en) 2012-01-12
PT2099758E (pt) 2016-06-02
IL199083A0 (en) 2010-03-28
CA2669819C (en) 2016-08-30

Similar Documents

Publication Publication Date Title
EA200970535A1 (ru) Антибактериальные производные хинолина
EA200970534A1 (ru) Антибактериальные производные хинолина
HK1137431A1 (en) Antibacterial quinoline derivatives
EA201491982A1 (ru) Антибактериальные хинолиновые производные
EA200970536A1 (ru) Антибактериальные хинолиновые производные
JO2685B1 (en) Quinoline antibacterial derivatives
SG166799A1 (en) Quinoline derivatives as antibacterial agents
EA200970537A1 (ru) Антибактериальные производные хинолина
EA201491971A1 (ru) Антибактериальные хинолиновые производные
EA201491992A1 (ru) Новые соединения и новое применение